Similar frequencies of Pseudomonas aeruginosa isolates producing KPC and VIM carbapenemases in diverse genetic clones at tertiary-care hospitals in Medellín, Colombia

Journal of Clinical Microbiology
Johanna M VanegasJ Natalia Jiménez


Carbapenem-resistant Pseudomonas aeruginosa has become a serious health threat worldwide due to the limited options available for its treatment. Understanding its epidemiology contributes to the control of antibiotic resistance. The aim of this study was to describe the clinical and molecular characteristics of infections caused by carbapenem-resistant P. aeruginosa isolates in five tertiary-care hospitals in Medellín, Colombia. A cross-sectional study was conducted in five tertiary-care hospitals from June 2012 to March 2014. All hospitalized patients infected by carbapenem-resistant P. aeruginosa were included. Clinical information was obtained from medical records. Molecular analyses included PCR for detection of bla(VIM), bla(IMP), bla(NDM), bla(OXA-48), and bla(KPC) genes plus pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) for molecular typing. A total of 235 patients were enrolled: 91.1% of them were adults (n = 214), 88.1% (n = 207) had prior antibiotic use, and 14.9% (n = 35) had urinary tract infections. The bla(VIM-2) and bla(KPC-2) genes were detected in 13.6% (n = 32) and 11.5% (n = 27), respectively, of all isolates. Two isolates harbored both genes simultaneously. For KPC-producing i...Continue Reading


Jan 1, 1984·The Journal of Antimicrobial Chemotherapy·K S ThomsonT J Regan
Dec 8, 2004·Journal of Clinical Microbiology·Barry CurranChristopher G Dowson
Aug 30, 2005·Current Opinion in Microbiology·Jodi M Thomson, Robert A Bonomo
Dec 23, 2006·The Journal of Antimicrobial Chemotherapy·Matthew J EllingtonN Woodford
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·M V VillegasColombian Nosocomial Resistance Study Group
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Jan 3, 2009·Journal of Korean Medical Science·Pinar OnguruMustafa Aydin Cevik
Feb 20, 2009·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Jian-Fang ZhangZhi-Kai Xu
Jun 6, 2009·Journal of Clinical Microbiology·Patrick E AkpakaM V Villegas
Apr 28, 2010·Antimicrobial Agents and Chemotherapy·Laurent PoirelL Silvia Munoz-Price
Jun 1, 2010·International Journal of Antimicrobial Agents·Canan KulahPaul H M Savelkoul
Mar 15, 2011·Diagnostic Microbiology and Infectious Disease·Laurent PoirelP Nordmann
Aug 17, 2011·Antimicrobial Agents and Chemotherapy·G CuzonP Nordmann
Nov 4, 2011·International Journal of Antimicrobial Agents·David P NicolauEllie J C Goldstein
Apr 10, 2012·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Gisela SantellaMarcela Radice
Jul 25, 2012·Antimicrobial Agents and Chemotherapy·A CorreaM V Villegas
Dec 4, 2012·The Journal of Hospital Infection·A NakamuraA Ohsaka
Jun 19, 2013·BMC Microbiology·Margarita GomilaJorge Lalucat
Nov 22, 2013·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·A CarattoliN Petrosillo
Jan 16, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A A WitneyJ Hinds
Apr 22, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Satoshi YamaguchiYuichi Ohashi


Dec 6, 2016·Expert Review of Anti-infective Therapy·Kevin Escandón-VargasM V Villegas
Dec 28, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Theodoros KarampatakisEmmanuel Roilides
Sep 19, 2019·Biomédica : revista del Instituto Nacional de Salud·Carlos Andrés Vargas-AlzateJudy Natalia Jiménez-Quiceno
Jul 24, 2019·Antibiotics·Tatiana PachecoJavier Escobar-Perez
Apr 10, 2019·Antibiotics·Emily M Eichenberger, Joshua T Thaden
Sep 19, 2019·Biomédica : revista del Instituto Nacional de Salud·Ana Mercedes RadaM V Villegas
Nov 6, 2020·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqD M Livermore

Related Concepts

Related Feeds


Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.